FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118028203> ?p ?o ?g. }

• W2118028203 endingPage "140" @default.
• W2118028203 startingPage "127" @default.
• W2118028203 abstract "Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking. A base-case analysis compared expected benefits of adalimumab therapy with a 12-week stopping rule for non-responders versus non-biologic therapies using data from clinical trials (CHARM, CLASSIC I). Adverse events (AEs) recorded in clinical trials (CHARM, CLASSIC I, CLASSIC II, GAIN, open-label extensions) were compiled. Sensitivity analyses incorporated all observed benefits of adalimumab and placebo (CHARM, CLASSIC I, GAIN) and observed AEs from a systematic literature review of non-biologic therapies (MEDLINE search of randomized trials 1990–2007). Distributional information from maintenance clinical trial observations and benefit model predictions were used in a probabilistic simulation. Incremental net benefits were estimated based on utility estimates from the literature. Average time in remission (i.e., CDAI <150) over 1 year of therapy was 39.9% for adalimumab versus 6.6% for traditional non-biologic therapies. Adalimumab was associated with fewer expected hospitalizations, better fistula closure rates, and lower AE rates. These findings were robust in sensitivity analyses. In the probabilistic simulation, with serious AEs as a composite of risks, adalimumab provided greater benefits with fewer AEs versus non-biologic therapies (P < 0.01). Adalimumab demonstrated greater incremental net quality-adjusted life-years (0.12) versus non-biologic therapies. Adalimumab demonstrated greater benefits and lower rates of AEs versus traditional non-biologic therapies for patients with moderately to severely active CD who were refractory to non-biologic therapies. (Inflamm Bowel Dis 2011;)" @default.
• W2118028203 created "2016-06-24" @default.
• W2118028203 creator A5039244845 @default.
• W2118028203 creator A5040838985 @default.
• W2118028203 creator A5046814722 @default.
• W2118028203 creator A5050304186 @default.
• W2118028203 creator A5053225263 @default.
• W2118028203 creator A5089194015 @default.
• W2118028203 date "2011-01-01" @default.
• W2118028203 modified "2023-10-18" @default.
• W2118028203 title "Risk–benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohnʼs disease" @default.
• W2118028203 cites W1964785646 @default.
• W2118028203 cites W1966122948 @default.
• W2118028203 cites W1971012473 @default.
• W2118028203 cites W1971740020 @default.
• W2118028203 cites W1978145728 @default.
• W2118028203 cites W1991810959 @default.
• W2118028203 cites W1994020662 @default.
• W2118028203 cites W2000997159 @default.
• W2118028203 cites W2001681806 @default.
• W2118028203 cites W2002451630 @default.
• W2118028203 cites W2007498173 @default.
• W2118028203 cites W2014298657 @default.
• W2118028203 cites W2017295150 @default.
• W2118028203 cites W2022253360 @default.
• W2118028203 cites W2024162533 @default.
• W2118028203 cites W2027297533 @default.
• W2118028203 cites W2027812459 @default.
• W2118028203 cites W2031443391 @default.
• W2118028203 cites W2037707239 @default.
• W2118028203 cites W2046881946 @default.
• W2118028203 cites W2055211617 @default.
• W2118028203 cites W2058321458 @default.
• W2118028203 cites W2059775920 @default.
• W2118028203 cites W2090198994 @default.
• W2118028203 cites W2092112762 @default.
• W2118028203 cites W2095164057 @default.
• W2118028203 cites W2104387234 @default.
• W2118028203 cites W2113591882 @default.
• W2118028203 cites W2116048670 @default.
• W2118028203 cites W2118422544 @default.
• W2118028203 cites W2118882175 @default.
• W2118028203 cites W2120419234 @default.
• W2118028203 cites W2121609590 @default.
• W2118028203 cites W2123934318 @default.
• W2118028203 cites W2125647281 @default.
• W2118028203 cites W2128890061 @default.
• W2118028203 cites W2131727319 @default.
• W2118028203 cites W2136419595 @default.
• W2118028203 cites W2137599445 @default.
• W2118028203 cites W2137775651 @default.
• W2118028203 cites W2138223843 @default.
• W2118028203 cites W2141139109 @default.
• W2118028203 cites W2152026434 @default.
• W2118028203 cites W2162766966 @default.
• W2118028203 cites W2164237757 @default.
• W2118028203 cites W2164861161 @default.
• W2118028203 cites W2166360124 @default.
• W2118028203 cites W2321453230 @default.
• W2118028203 cites W2326330820 @default.
• W2118028203 cites W2326745462 @default.
• W2118028203 cites W2331622494 @default.
• W2118028203 cites W2340424973 @default.
• W2118028203 cites W2342066803 @default.
• W2118028203 cites W4236521244 @default.
• W2118028203 doi "https://doi.org/10.1002/ibd.21341" @default.
• W2118028203 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20848523" @default.
• W2118028203 hasPublicationYear "2011" @default.
• W2118028203 type Work @default.
• W2118028203 sameAs 2118028203 @default.
• W2118028203 citedByCount "9" @default.
• W2118028203 countsByYear W21180282032012 @default.
• W2118028203 countsByYear W21180282032013 @default.
• W2118028203 countsByYear W21180282032014 @default.
• W2118028203 countsByYear W21180282032015 @default.
• W2118028203 countsByYear W21180282032017 @default.
• W2118028203 crossrefType "journal-article" @default.
• W2118028203 hasAuthorship W2118028203A5039244845 @default.
• W2118028203 hasAuthorship W2118028203A5040838985 @default.
• W2118028203 hasAuthorship W2118028203A5046814722 @default.
• W2118028203 hasAuthorship W2118028203A5050304186 @default.
• W2118028203 hasAuthorship W2118028203A5053225263 @default.
• W2118028203 hasAuthorship W2118028203A5089194015 @default.
• W2118028203 hasBestOaLocation W21180282031 @default.
• W2118028203 hasConcept C126322002 @default.
• W2118028203 hasConcept C142724271 @default.
• W2118028203 hasConcept C143998085 @default.
• W2118028203 hasConcept C168563851 @default.
• W2118028203 hasConcept C197934379 @default.
• W2118028203 hasConcept C204787440 @default.
• W2118028203 hasConcept C27081682 @default.
• W2118028203 hasConcept C2779134260 @default.
• W2118028203 hasConcept C2779280984 @default.
• W2118028203 hasConcept C2780132546 @default.
• W2118028203 hasConcept C535046627 @default.
• W2118028203 hasConcept C71924100 @default.
• W2118028203 hasConceptScore W2118028203C126322002 @default.
• W2118028203 hasConceptScore W2118028203C142724271 @default.

• next